CAR T-cell therapy successfully treats myeloma in Hong Kong
A CAR T-cell therapy manufactured in mainland China has been successfully deployed for the first time in Hong Kong to treat a man with myeloma,…
Myeloma
Personalized cancer vaccine shows potential in myeloma, solid tumors
A personalized cancer vaccine called PGV001 showed potential in combating several types of cancer, both solid tumors and blood malignancies like myeloma, in a…
2nd Iceland Cycling Expedition aims to raise myeloma research funds
The International Myeloma Foundation (IMF) has announced its 2nd annual Iceland Cycling Expedition (ICE), a seven-day endurance bike ride to raise funds for…
Use of dexamethasone may manage Tecvayli’s immune side effect: Study
The use of dexamethasone alone may successfully treat the immune side effect cytokine release syndrome (CRS) in people with relapsed or refractory multiple…
March’s Myeloma Action Month means sharing patient milestones
This year’s Myeloma Action Month (MAM), which is observed each March, is focused on celebrating and sharing patient milestones to help call…
High-risk genetic changes with myeloma tied to poorer outcomes
The presence of more than one high-risk genetic abnormality is associated with dramatically more aggressive multiple myeloma, a study reported. Its findings highlight the…
FDA decision on linvoseltamab in treating RRMM expected in July
The U.S. Food and Drug Administration (FDA) has agreed to review an application from Regeneron Pharmaceuticals seeking the approval of linvoseltamab to treat…
Complete response to CAR T-cell therapy reported in RRMM patient
A first patient with relapsed/refractory multiple myeloma (RRMM) treated with CT0590, Carsgen Therapeutics’ CAR T-cell therapy, showed a complete response to the…
Researchers generate plasma cell dataset to aid myeloma diagnosis
Researchers in Brazil have developed a large dataset of cells taken from the bone marrow of people with multiple myeloma (MM) and other blood…
Sarclisa approved in EU for adults new to MM and transplant ineligible
Regulators in the European Union (EU) have approved Sarclisa (isatuximab) in combination with standard-of-care medications for adults newly diagnosed with multiple myeloma who…
